Loading clinical trials...
Loading clinical trials...
Post Marketing Surveillance (PMS) Study for Cibinqo Tablet (Abrocitinib) in Patients With Moderate to Severe Atopic Dermatitis (AD) in Korea
Conditions
Interventions
Abrocitinib
Locations
1
South Korea
Pfizer Tower
Seoul, South Korea
Start Date
January 7, 2023
Primary Completion Date
November 22, 2027
Completion Date
November 22, 2027
Last Updated
December 9, 2025
NCT06488742
NCT05250115
NCT04975438
NCT03563066
NCT04011215
NCT05177744
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions